Responses
Regular and young investigator award abstracts
Regulatory, financial, and access considerations
731 Costs of care for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): a real-world claims analysis
Compose a Response to This Article
Other responses
No responses have been published for this article.
